Galapagos N.V. (GLPG) Stock Analysis & Investment Frameworks
Galapagos N.V. (GLPG) stock analysis on Invetso. Review Galapagos N.V.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Galapagos N.V. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: BE
Galapagos N.V. Key Financial Metrics
- Market Cap: $1.84B
- Revenue: $1.24B
- P/E Ratio: 5.15
- ROE: 19.88%
- ROIC: 12.31%
- Dividend Yield: N/A
About Galapagos N.V.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.